Skip to main content
B

Beijing Strong Biotechnologies, Inc — Investor Relations & Filings

Ticker · 300406 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,949 across all filing types
Latest filing 2026-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300406

About Beijing Strong Biotechnologies, Inc

https://www.bsbe.com.cn

Beijing Strong Biotechnologies, Inc. (BSBE) specializes in the research, development, manufacture, and distribution of in vitro diagnostic (IVD) products. The company’s core portfolio includes a comprehensive range of clinical chemistry reagents, such as those for liver and kidney function, lipid profiles, and cardiovascular markers. BSBE also develops automated diagnostic instruments, including chemiluminescence immunoassay systems and coagulation analyzers. The company is recognized for its commitment to standardization and quality control, providing reference materials and participating in international traceability initiatives. Its products serve clinical laboratories, hospitals, and medical institutions, supported by strategic collaborations with global diagnostic leaders to enhance laboratory efficiency and diagnostic accuracy.

Recent filings

Filing Released Lang Actions
董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 1% confidence The document is a formal report by the Board’s Audit Committee assessing the external auditor’s performance and oversight duties for the 2025 fiscal year. It is not the full annual report nor an earnings release, but rather an audit‐related disclosure distinct from the auditor’s opinion itself. This falls under the standalone audit information category, as it provides audit committee evaluation and oversight commentary, rather than being a management discussion or governance charter. Therefore it best fits “Audit Report / Information (AR).”
2026-04-26 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 1% confidence The document is a board-issued special opinion on the independence of its independent directors, citing governance rules and exchange guidelines. It does not announce board changes, financial results, or meeting materials, but relates to the company’s governance practices regarding director independence. This fits “Governance Information (CGR).”
2026-04-26 Chinese
2025年年度审计报告
Audit Report / Information Classification · 1% confidence The document is a full audit report issued by LixinZhonglian CPAs (审计报告) for Beijing九强生物技术股份有限公司, containing auditor’s opinion, basis of audit, key audit matters, responsibilities, and complete financial statements with notes. This matches the definition of a standalone Audit Report / Information (excluding a full annual report). Therefore, it should be classified as AR.
2026-04-26 Chinese
2025年度财务决算报告
Interim / Quarterly Report Classification · 1% confidence The document is a '2025 Annual Financial Final Accounts Report' (2025年度财务决算报告) for Beijing Getein Biotech Co., Ltd. It contains detailed comparative financial statements (balance sheet, income statement, cash flow), analysis of financial indicators, and management's explanation of business trends and performance. While it is not the full audited Annual Report (10-K), it provides substantive financial data and analysis for the fiscal year, fitting the definition of an Interim/Quarterly Report (IR) or a comprehensive management financial report. Given the depth of the financial data and the fact that it is a standalone report on the year's financial results, it is classified as an Interim/Quarterly Report (IR) as it serves as a comprehensive financial report for the period. FY 2025
2026-04-26 Chinese
关于公司取得医疗器械注册证书的公告
Regulatory Filings Classification · 1% confidence The document is an announcement by Beijing Jiuzhuang Biotech Co., Ltd. regarding the receipt of medical device registration certificates from the Beijing Drug Supervision Administration. It contains no information on financial results, dividends, share issues, management changes, or AGMs. Instead, it is a general corporate regulatory announcement about product approvals. Therefore, it falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-04-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 1% confidence The document is a formal announcement (“公告”) by Beijing Jiuliang Biotechnology Co., Ltd. regarding changes in its accounting policies to comply with new regulatory guidelines (CSRC’s Accounting Guideline No.5 and MoF’s Interpretation No.19). It is not a full financial report, audit opinion, or investor presentation, but rather a regulatory disclosure about policy changes. It does not fit into more specific categories (e.g., board changes, dividends, share issues). Therefore, it falls under “Regulatory Filings” as a general announcement of company information per disclosure rules.
2026-04-26 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.